Study for the effect of SGLT2 inhibitors in high risk patients of dialysis with type 2 diabetes
- Conditions
- type 2 diabetes
- Registration Number
- JPRN-UMIN000035263
- Lead Sponsor
- Kurihara Naika Clinic
- Brief Summary
%DeGFR+2y in patients who were treated with SGLT2i was significantly increased compared with the patients not treated with SGLT2i (2.3 and -21.7%, respectively; P < 0.0001). There was no increase in serious adverse events including acute kidney injury. SGLT2i was safe, and prevented further eGFR decline in patients with type 2 diabetes and advanced renal dysfunction.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 75
Not provided
1)type 1 diabetes 2)severe liver dysfunction 3)pregnancy, nursing woman or possibly pregnant woman 4)severe diabetic ketosis, diabetic coma 5)severe infection, pre and post operation , severe trauma 7) uncontrolled diet therapy 8) poor adherence for medication 9) patients who thought to be inappropriate to enter this study for some reasons by physician's judgments
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in eGFR decline rate between before and after 2 years of SGLT2 inhibitors administration
- Secondary Outcome Measures
Name Time Method Glycemic control Weight Blood pressure Blood and Urine test (Liver, Kidney function, lipid, UA) Characteristics of patients who well responded to SGLT2 inhibitors Comparison of eGFR decline change with that in non-SGLT2 inhibitors users who were matched background